Impact of Cernitin™ on induced chronic prostatitis in animal model for understanding management of lower urinary tract symptoms
| Autor: | Per-Anders Abrahamsson, Lena Ramnemark, Philippe Lluel, Sophie Chabot, Magnus Grabe, Nishtman Dizeyi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Benign prostatic hyperplasia
business.industry Pelvic pain General Engineering Cernitin™ Prostatitis Parallel study Physiology Hyperplasia medicine.disease Other systems of medicine medicine.anatomical_structure Lower urinary tract symptoms In vivo Prostate medicine General Earth and Planetary Sciences Cytokines Cernilton® medicine.symptom business Testosterone RZ201-999 General Environmental Science |
| Zdroj: | Phytomedicine Plus, Vol 1, Iss 4, Pp 100057-(2021) |
| ISSN: | 2667-0313 |
| Popis: | Background Cernitin™ pollen extracts (brand name Cernilton®) alleviates symptoms related to common lower uro-genital tract disorders in men. The underlying mechanisms are ill-defined but the inflammatory pathway could be one of them. In a previous in vitro study it was shown that Cernitin™ induce a regulatory effect on inflammatory parameters. Methods In this study, male Sprague Dawley rats were used to validate the effects of Cernitin™ in chronic prostatitis and benign prostatic hyperplasia. Pain was assessed by von Frey assay. Results Cernitin™ exhibited significant pain relief in the induced prostatitis rat model and was associated with a significant decrease in the intraprostatic level of COX-2 and MCP-1 in the prostatic tissue homogenates. In a parallel study, Cernitin™ treatment led to a significant decrease in prostate weight in rats with testosterone induced BPH. Concurrently, a significant decrease in the percentage of proliferation marker, Ki-67, and androgen receptor expressing cells was observed. Similarly, a low level of cytoplasmic 5α-reductase expression was observed in Cernitin™- and finasteride-treated animals. Conclusion The current in vivo experiments support the use of Cernitin™ as an anti-inflammatory and symptom reducing agent that could, in part, explain the impact of Cernitin™ on the management of chronic pelvic pain in men. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|